Alimera Sciences Investor Relations Material

Latest events

Q4 2023

Alimera Sciences

Q4 2023

7 Mar, 2024

Q3 2023

26 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Alimera Sciences Inc

Access all reports
Alimera Sciences is a pharmaceutical company that develops and commercializes ophthalmic pharmaceuticals. We market ILUVEN, an intravitreal implant for the treatment of diabetic macular edema (DME) which is a disease of the retina that affects individuals with diabetes and leads to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. Our products can be purchased directly from our website or through authorized distributors. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.